Get the Daily Brief
Latest Biotech News
Regeneron’s Rare Disease Win Drives FDA Filing Plans
Regeneron Pharmaceuticals announced topline success in its phase III Optima trial for garetosmab, a monoclonal antibody targeting fibrodysplasia ossificans progressiva (FOP), a rare skeletal...
AI Designs Complete Genomes to Combat Antibiotic Resistance
Researchers at Stanford University and the Arc Institute have harnessed artificial intelligence to design complete, functional bacteriophage genomes, marking a breakthrough in genome engineering....
Biotech Investment Surges as GSK Commits $30 Billion to U.S.
GlaxoSmithKline (GSK) announced a $30 billion investment plan over five years to expand drug manufacturing, research, and clinical trials in the United States, reinforcing its commitment to its...
Areteia Posts Phase 3 Success in Eosinophilic Asthma
Areteia Therapeutics reported positive phase 3 results for dexpramipexole, an oral small molecule targeting eosinophilic asthma. The Exhale-4 trial met its primary endpoint, demonstrating...
Ollin Biosciences Launches with $100M to Challenge Eye Drug Leaders
Newly launched Ollin Biosciences emerged from stealth with $100 million in venture capital to develop next-generation ophthalmology treatments. Co-founded by former Genentech ophthalmologist Jason...
Advances in Gene Therapy and CRISPR Technologies Accelerate Personalized Medicine
Aldevron, IDT, and partners collaborated with the FDA to rapidly develop and deliver the world’s first personalized mRNA-based CRISPR therapy for a baby with a rare metabolic disorder, completing...
New Diagnostic and Predictive Tools Transform Cancer Detection and Treatment
Innovative technologies from multiple research teams are reshaping cancer diagnostics and therapeutic monitoring. The University of Birmingham developed a urine test detecting bladder cancer via...
Manufacturing and Process Innovations Optimize Biologic and Gene Therapy Production
Industry advances are driving greater efficiency in biologics and viral vector manufacturing. Sanofi demonstrates intensified fed-batch processing with high-density seeding and simplified feeding...
Vaccine Policy Turmoil and CDC Leadership Shakeup Reverberate in Public Health
The U.S. CDC faces unprecedented upheaval as former director Susan Monarez testified that Health and Human Services Secretary Robert F. Kennedy Jr. demanded her to approve vaccine recommendations...
Roivant’s Brepocitinib Hits Phase 3 Target in Rare Dermatomyositis
Roivant and Priovant announced a successful Phase 3 trial for brepocitinib, a TYK2/JAK1 inhibitor, in dermatomyositis. The drug demonstrated significant symptom reduction over placebo in a 52-week...
GSK Commits $30 Billion to U.S. Manufacturing and R&D Expansion
GlaxoSmithKline announced a $30 billion investment plan over five years enhancing drug production, discovery, and clinical trials in the United States. This move intensifies GSK’s focus on its...
AI Designs Functional Viruses to Kill Bacteria
Researchers at Stanford and the Arc Institute used artificial intelligence models trained on millions of bacteriophage genomes to design new viral genomes. Of 302 AI-generated genetic designs...
Colossal Biosciences Raises $120M to Advance De-Extinction Projects
Colossal Biosciences has expanded its Series C funding round with an additional $120 million, bringing total raised to over $555 million since inception. The Dallas-based company focuses on...
Lilly’s Oral GLP-1 Pill Outperforms Novo Nordisk’s in Diabetes Trial
Eli Lilly announced that its investigational oral GLP-1 receptor agonist, orforglipron, achieved superior blood sugar control and weight reduction compared to Novo Nordisk’s oral Rybelsus in a...
Dualitas Therapeutics Launches with $65M to Develop Bispecific Antibodies for Immune Diseases
Dualitas Therapeutics emerged from stealth mode following a $65 million Series A financing co-led by Versant Ventures and Qiming Venture Partners USA. The Bay Area biotech aims to develop...
Alchemab Therapeutics Raises $32M to Propel Antibody Pipeline and Lilly Collaboration
UK-based Alchemab expanded its Series A financing round by $32 million, bringing the total to $114 million to advance its AI-driven antibody discovery platform. The funding will support...
Next-Gen Cancer Immunotherapy Platform: MIT’s Antibody-Bottlebrush Conjugates
Scientists at MIT developed antibody-bottlebrush conjugates (ABCs), a novel cancer therapy platform that vastly increases drug-to-antibody ratios compared to traditional antibody-drug conjugates...
New CRISPR-Based Tongue Swab Test Transforms Tuberculosis Screening
Tulane University researchers developed ActCRISPR-TB, an innovative assay integrating isothermal amplification and CRISPR-Cas12a in a single reaction to detect Mycobacterium tuberculosis DNA from...
Synthesize Bio Launches with $10M Seed to Accelerate AI-Driven Drug Discovery
Seattle-based Synthesize Bio announced its launch backed by a $10 million seed round led by Madrona, focusing on generative AI biological foundation models for improving drug discovery and design....
Novartis, Monte Rosa Boost Immune Drug Pipeline With $5.7B Molecular Glue Deal
Novartis has expanded its collaboration with Monte Rosa Therapeutics, committing up to $5.7 billion to develop molecular glue degraders targeting immune-mediated diseases. The deal includes an...